

Certificate of Mailing

"Express Mail" mailing label number EV 330 963 920 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 25, 2003.

By: Diane Kizer

Printed: Diane Kizer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Au-Young et al.

Title: CYCLIC NUCLEOTIDE PHOSPHODIESTERASE

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of references 1-16 are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/454,060 filed December 12, 1999, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Date:

July 25, 2003

Gina C. Nellesen

Gina C. Nellesen

Reg. No. 52,062

Direct Dial Telephone: (650) 843-7342

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0057-4 CON	To Be Assigned
LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)	Applicants Au-Young et al.	
	Filing Date	Group
	Herewith	To Be Assigned

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents

		Document	Date	Country	Class	Subclass	Yes	No	Translation

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Angel, J.B. et al., "Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication", <u>AIDS</u> (1995) 9:1137-1144.
2	Bang, Y.J. et al., "Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP", <u>Proc Natl Acad Sci USA</u> (1994) 91:5330-5334.
3	Banner, K.H. and Page, C.P., "Immunomodulatory actions of xantines and isoenzyme selective phosphodiesterase inhibitors", <u>Mondaldi Arch Chest Dis</u> (1995) 50:4,286-292.
4	Banner, K.H. and Page, C.P., "Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma", <u>Eur Respir J</u> (1995) 8:996-1000.
5	Beavo, Joseph A., "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", <u>Physiological Reviews</u> (1995) 75:725-747.
6	Deonarain, M.P. and Epenetos, A.A., "Targeting enzymes for cancer therapy: old enzymes in new roles", <u>Br J Cancer</u> 70:786-794.
7	Joulain, C. et al., "Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation", <u>J Lipid Mediators Cell Signalling</u> (1995) 11:63-79.
8	Matousovic, K. et al., "Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells", <u>J Clin Invest</u> (1995) 96:401-410.
9	Sasaki, H. et al., "Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol", <u>European Journal of Pharmacology</u> (1995) 282:71-76.

Examiner	Date Considered
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)